Evidence map›Paper›PMID 41238736›Full record

ArticleScientific reports2025

Evaluation of progesterone receptors with different cutoff values according to menopausal status in hormone-positive early breast cancer.

Ayumi Ogawa, Takeshi Murata, Masayuki Yoshida, Natsuko Ohgi, Hiromi Hashiguchi, Ayako Nakashoji, Hinako Maeda, Chikashi Watase, Eriko Iwamoto, Shin Takayama

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ayumi OgawaDepartment of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Takeshi MurataDepartment of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. tamurata@ncc.go.jp.
Masayuki YoshidaDepartment of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Natsuko OhgiDepartment of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hiromi HashiguchiDepartment of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Ayako NakashojiDepartment of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Hinako MaedaDepartment of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Chikashi WataseDepartment of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Eriko IwamotoDepartment of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Shin TakayamaDepartment of Breast Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The impact of progesterone receptor (PR) expression level on breast cancer prognosis in relation to menopausal status is unclear. This study evaluated the impact of the association between PR expression level and menopausal status on prognosis in patients with estrogen receptor (ER)-positive (> 10%)/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. We retrospectively identified 2,796 patients with ER-positive/HER2-negative early breast cancer and classified them into three groups based on PR expression levels: PR-high (> 10%), PR-low (1-10%), and PR-zero (< 1%). We compared the cumulative incidence of any recurrence (AR) and distant recurrence (DR) among the three groups by menopausal status. Over a median follow-up of 84.5 months, there were 324 AR and 264 DR events. In premenopausal patients, the PR-zero group (1,155 patients) had a significantly worse prognosis than did the PR-low (44 patients) and PR-high (60 patients) groups. Meanwhile, postmenopausal patients in the PR-zero (219 patients) and PR-low (167 patients) groups had similar prognosis, both significantly worse than the PR-high group (1,151 patients). Varying cutoff values of PR expression according to menopausal status could help determine more personalized treatment strategies.

Indexed as

Breast NeoplasmsMenopauseReceptors, ProgesteroneAdultAgedBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoplasm Recurrence, LocalPrognosisReceptors, EstrogenRetrospective StudiesBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBreast cancerHormone receptor-positiveLow-positiveMenopausal statusProgesterone receptor

Identifiers

PMID41238736
PMCPMC12618652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.